Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
Open Access
- 6 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (12), 3136-3143
- https://doi.org/10.1093/cid/ciz1212
Abstract
There is marked interindividual variability in metabolism and resulting toxicity and effectiveness of drugs used for tuberculosis treatment. For isoniazid, mutations in the N-acetyltransferase 2 (NAT2) gene explain >88% of pharmacokinetic variability. However, weight-based dosing remains the norm globally. The potential clinical impact and cost-effectiveness of pharmacogenomic-guided therapy (PGT) are unknown. We constructed a decision tree model to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazil, South Africa, and India. PGT was modeled to reduce isoniazid toxicity among slow NAT2 acetylators and reduce treatment failure among rapid acetylators. The genotyping test was assumed to cost the same as the GeneXpert test. The main outcomes were costs (2018 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. In Brazil, PGT gained 19 discounted life-years (23 QALYs) and cost $11 064 per 1000 patients, a value of $476 per QALY gained. In South Africa, PGT gained 15 life-years (19 QALYs) and cost $33 182 per 1000 patients, a value of $1780 per QALY gained. In India, PGT gained 20 life-years (24 QALYs) and cost $13 195 per 1000 patients, a value of $546 per QALY gained. One-way sensitivity analyses showed the cost-effectiveness to be robust to all input parameters. Probabilistic sensitivity analyses were below per capita gross domestic product in all 3 countries in 99% of simulations. Isoniazid PGT improves health outcomes and would be cost-effective in the treatment of drug-susceptible tuberculosis in Brazil, South Africa, and India.Funding Information
- United States Fulbright Program and the Holland Scholarship
This publication has 30 references indexed in Scilit:
- NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysisThe International Journal of Tuberculosis and Lung Disease, 2019
- Comparison of Two Point-of-Care CYP2C19 Genotyping Assays for Genotype-Guided Antiplatelet Therapy.2017
- Disability weights for the Global Burden of Disease 2013 studyThe Lancet. Global Health, 2015
- A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosisDrug Design, Development and Therapy, 2015
- Future of pharmacogenetics-based therapy for tuberculosisPharmacogenomics, 2014
- What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?PLOS ONE, 2013
- Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype dataBMC Medical Genetics, 2009
- An Official ATS Statement: Hepatotoxicity of Antituberculosis TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Isoniazid-associated Hepatitis Deaths: A Review of Available InformationAmerican Review of Respiratory Disease, 1992
- Twenty Isoniazid-associated Deaths in One StateAmerican Review of Respiratory Disease, 1989